Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line.

Marcuzzi A, Zanin V, Piscianz E, Tricarico PM, Vuch J, Girardelli M, Monasta L, Bianco AM, Crovella S.

Int J Dev Neurosci. 2012 Oct;30(6):451-6. doi: 10.1016/j.ijdevneu.2012.06.002. Epub 2012 Jul 1.

PMID:
22759742
2.

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA.

Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133-8.

3.

Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells.

Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM.

J Biol Chem. 2002 May 3;277(18):15309-16. Epub 2002 Feb 11.

4.

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.

Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ.

Clin Cancer Res. 2001 Jan;7(1):158-67.

5.

Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines.

Wang W, Macaulay RJ.

Can J Neurol Sci. 1999 Nov;26(4):305-10.

PMID:
10563217
6.

Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.

Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D.

Cancer. 2012 Feb 1;118(3):750-60. doi: 10.1002/cncr.26336. Epub 2011 Jul 12.

7.

Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells.

Wang IK, Lin-Shiau SY, Lin JK.

Pharmacol Toxicol. 2000 Feb;86(2):83-91.

PMID:
10728920
10.

Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.

Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ.

Clin Cancer Res. 2001 Jul;7(7):2067-75.

11.

Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells.

Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ.

J Neurochem. 1998 Jun;70(6):2397-405.

12.

Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome.

Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM, Wanders RJ, Waterham HR, Kuis W.

Arthritis Rheum. 2002 Oct;46(10):2794-803.

13.

Geranylgeraniol restores cell proliferation to lovastatin treated C6 glial cells.

Crick DC, Waechter CJ, Andres DA.

SAAS Bull Biochem Biotechnol. 1996;9:37-42.

PMID:
8652130
14.

Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.

McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H.

Exp Biol Med (Maywood). 2007 Apr;232(4):523-31.

PMID:
17392488
15.

Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.

Tricarico PM, Piscianz E, Monasta L, Kleiner G, Crovella S, Marcuzzi A.

Apoptosis. 2015 Aug;20(8):1048-55. doi: 10.1007/s10495-015-1139-8.

PMID:
26003816
16.

Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.

Bi X, Baudry M, Liu J, Yao Y, Fu L, Brucher F, Lynch G.

J Biol Chem. 2004 Nov 12;279(46):48238-45. Epub 2004 Sep 9.

17.

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.

Dimitroulakos J, Lorimer IA, Goss G.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4426s-4431s. Review.

18.

Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.

Kaneko R, Tsuji N, Asanuma K, Tanabe H, Kobayashi D, Watanabe N.

J Biol Chem. 2007 Jul 6;282(27):19273-81. Epub 2007 May 1.

19.

Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells.

Choi JW, Jung SE.

J Pharmacol Exp Ther. 1999 Apr;289(1):572-9.

20.

Supplemental Content

Support Center